Caremark Reaps Pricing Benefit From AdvancePCS Acquisition
This article was originally published in The Pink Sheet Daily
The PBM is looking for additional mergers and acquisitions outside pharmacy benefit management.
You may also be interested in...
Teva and Ranbaxy appear slated for 180 days of simvastatin exclusivity after federal court ruling postponing mass generic entry into the sector until 2007.
Watson concurrently launched an authorized generic of Bristol's pravastatin, but Ranbaxy's 80 mg ANDA remains on hold.
The $137.5 mil. settlement requires Caremark to inform client plans of rebates earned as a percentage of the PBM’s total product revenue.